Search

Search Results

• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  A.G. Turkina, O. Yu. Vinogradova, E.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov

  1-13

  01.01.2026

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Treatment of Aggressive Systemic Mastocytosis and Mast Cell Leukemia. Literature Review and Case Reports

  Vsevolod Gennadevich Potapenko, E.V. Morozova

  180-194

  01.04.2024

• Treatment of Mastocytosis: A Literature Review

  Karina Maksimovna Chernavina, A.S. Orlova, E.A. Nikitin

  361-369

  01.07.2021

• Mastocytosis in Adults: A Retrospective Analysis of the Clinical Course and Treatment of 58 Patients

  Vsevolod Gennadevich Potapenko, V.V. Baikov, I.E. Belousova, E.A. Belyakova, M.V. Barabanshchikova, D.V. Zaslavsky, I.S. Zyuzgin, A.V. Klimovich, Yu.A. Krivolapov, T.G. Kulibaba, E.V. Lisukova, E.E. Leenman, L.A. Mazurok, A.M. Maksimova, E.V. Morozova, A.S. Nizamutdinova, K.A. Skoryukova, E.A. Ukrainchenko, N.V. Medvedeva

  158-166

  01.04.2021

• Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial

  Oleg Aleksandrovich Shukhov, A.N. Petrova, E.Yu. Chelysheva, A.V. Bykova, I.S. Nemchenko, A.G. Turkina

  1-12

  01.01.2021

• Diagnosis and Treatment of Clonal Myeloproliferative Neoplasms with Eosinophilia

  Irina Semenovna Nemchenko, N.N. Tsyba, A.G. Turkina, E.Yu. Chelysheva, O.A. Shukhov, A.M. Kovrigina, T.N. Obukhova

  161-169

  01.04.2020

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

  Vera Vyacheslavovna Tikhonova, M.A. Isakov, V.A. Misyurin, Yu.P. Finashutina, L.A. Kesaeva, N.A. Lyzhko, I.N. Soldatova, N.N. Kasatkina, E.N. Misyurina, A.V. Misyurin

  227-233

  01.07.2018

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

  Tat’yana Ivanovna Ionova, N.B. Bulieva, O.Yu. Vinogradova, T.A. Gritsenko, L.K. Kozlova, G.B. Kuchma, E.G. Lomaia, E.R. Machyulaitene, T.P. Nikitina, N.V. Novitskaya, A.Yu. Rodionova, E.I. Usacheva, T.V. Shneider

  206-217

  01.04.2017

• Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems

  L.R. Tilova, A.V. Savinkova, E.M. Zhidkova, O.I. Borisova, T.I. Fetisov, K.A. Kuzin, O.A. Vlasova, A.S. Antipova, O.Yu. Baranova, K.I. Kirsanov, G.A. Belitskii, M.G. Yakubovskaya, Ekaterina Andreevna Lesovaya

  235-249

  01.04.2017

• Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

  K.M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I.S. Martynkevich, M.S. Fominykh, N.A. Potikhonova, I.I. Zotova, V.Yu. Udal’eva, R.A. Golovchenko, N.V. Shakhvorostova, D.I. Shikhbabaeva, M.N. Zenina, S.A. Tiranova, S.A. Kudryashova, L.S. Martynenko, M.P. Ivanova, N.Yu. Tsybakova, E.V. Petrova, L.B. Polushkina, E.V. Kleina

  54-60

  01.01.2016

• Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia

  N.S. Lazorko, Elza Galaktionovna Lomaia, E.G. Romanova, E.I. Sbityakova, E.R. Machyulaitene, P.A. Butylin, A.Yu. Zaritskii

  302-308

  01.07.2015

• Mixed-Phenotype Acute Leukemia: Clinical and Laboratory Features, and Prognosis

  A.S. Antipova, Ol’ga Yur’evna Baranova, M.A. Frenkel’, N.N. Tupitsyn, N.A. Kupryshina, T.N. Obukhova, A.D. Shirin

  136-150

  01.04.2015

• First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

  Vasilii Anatol’evich Shuvaev, K.M. Abdulkadyrov, I.S. Martynkevich, M.S. Fominykh

  78–83

  01.01.2015

• Imatinib Generics: Myths and Reality (Literature Review and Our Experience)

  K.M. Abdulkadyrov, V.A. Shuvaev, M.S. Fominykh

  311-316

  01.07.2014

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014

• Association between HLA-DRB1 alleles and response to imatinib in chronic myeloid leukemia

  E.G. Ovsyannikova, I.L. Davydkin, E.A. Popov, L.V. Zaklyakova, B.N. Levitan

  312-317

  01.07.2013

• Quality of life and symptom profile in patients with chronic myeloid leukemia receiving dasatinib as а second-line therapy due to intolerance or resistance to imatinib

  T.I. Ionova, D.A. Fedorenko, T.P. Nikitina, K.A. Kurbatova

  166-176

  01.04.2013

• The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision

  E.Yu. Chelysheva, A.V. Galaktionova, A.G. Turkina

  157-165

  01.04.2013

• Cardiovascular complications of chronic myeloid leukemia treated with tyrosine kinase inhibitors

  G.E. Gendlin, L.M. Makeeva, E.I. Emelina, K.V. Shuikova, G.I. Storozhakov

  78-84

  01.01.2013